In particular, APL patients harboring exceedingly uncommon RARα::HNRNPC and RARα::THRAP3 fusions have been documented to achieve CR through the administration of venetoclax and hypomethylating agents such as azacytidine or decitabine (58, 59). This evidence concerns the gene THRAP3 and acute promyelocytic leukemia.